Massacesi Cristian sold $403K of BMY

Bristol Myers Squibb reported 56-week trial data showing Camzyos (mavacamten) reduced LVOT gradient in children with obstructive hypertrophic cardiomyopathy. Continuous Camzyos treatment showed a -48.1 mmHg change, similar to placebo-to-Camzyos switch. Adverse events were more frequent in the continuous Camzyos group.

Bristol Myers Squibb (BMY) reported 56-week data from a phase 3 trial of Camzyos in children aged 12-18, showing positive results for treating symptomatic obstructive hypertrophic cardiomyopathy.

Bristol-Myers Squibb reported that its drug Camzyos showed sustained efficacy in a 56-week Phase 3 pediatric trial. The SCOUT-HCM trial results were announced late Friday. The company did not disclose specific data in the brief announcement.

Bristol Myers Squibb (BMY) presented 56-week trial data for Camzyos in pediatric patients with obstructive hypertrophic cardiomyopathy. The study showed significant reductions in left ventricular outflow tract gradient with no severe adverse events. Camzyos received FDA approval for pediatric use in 2026. Additional data will be presented at the American Heart Association's Scientific Sessions 2026.

Bristol Myers Squibb's Camzyos showed consistent efficacy and safety in a 56-week Phase 3 trial for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). No patient had left ventricular ejection fraction fall below 50%. The trial included a 28-week placebo-controlled period and demonstrated significant reductions in Valsalva left ventricular outflow tract gradient. Additional data will be presented at the American Heart Association’s Scientific Sessions 2026.

The FDA approved Bristol Myers Squibb's CAMZYOS (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and pediatric patients weighing 30 kg or more. The approval follows positive results from the SCOUT-HCM trial, showing significant reductions in LVOT gradient and symptom improvements. CAMZYOS is the first FDA-approved therapy for pediatric oHCM.